A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors

Hoffmann-La Roche140 enrolled

Overview

This is an open-label, multicenter study designed to assess the safety, pharmacokinetics, pharmacodynamics and activity of Selicrelumab administered in combination with Atezolizumab (ATZ) in participants with metastatic or locally advanced solid tumors. The study will be conducted in two Parts (I and II), with Part I divided into Parts IA and IB. All participants will be followed up for survival until death or loss of follow-up after the last visit or withdrawal of consent.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

140

Conditions

Solid Tumors

Interventions

AtezolizumabDRUG

Atezolizumab will be administered as per the dosage regimen mentioned in respective arm descriptions.

SelicrelumabDRUG

Selicrelumab will be administered as per the dosage regimen mentioned in respective arm descriptions.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically confirmed diagnosis of locally advanced and/or metastatic solid tumors, which are not amenable to standard therapy * Part I: histologically confirmed diagnosis of advanced/metastatic small and large bowel carcinomas (small bowel and CRC), CPI-experienced non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) * Part II: CPI-experienced NSCLC patients must have experienced documented disease progression on or after PD-L1 or PD-1 inhibitor therapy (investigational or approved): screening tumor assessment should confirm prior progression * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Life expectancy greater than or equal to (\>/=) 16 weeks * Adequate hematologic and end organ function * Measurable disease per RECIST Version 1.1 * Ability to comply with the protocol requirements * Female participants of childbearing potential must have a negative pregnancy test (urine/serum) within seven days prior to the first study drug administration * For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of less than (\<) 1% per year during the treatment period and for at least 5 months after the last dose of study treatment * For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm during the treatment period and for at least 28 days after the last dose of study treatment Exclusion Criteria: * If one of the following laboratory results obtained within 14 days prior to the first study treatment (Cycle 1 Day 1) are: soluble interleukin 2 receptor (sCD25) greater than (\>) 2 × upper limit of normal (ULN); Serum ferritin \>1000 nanograms per milliliter (ng/mL) * Any approved anti-cancer therapy that includes chemotherapy, hormonal therapy, or radiotherapy within 2 weeks prior to the first dose of study treatment; the following is, however, allowed: Palliative radiotherapy for bone metastases less than or equal to (\</=) 2 weeks prior to Cycle 1 Day 1 * Adverse events from prior anti-cancer therapy that have not resolved to Grade \</= 1 except for any grade alopecia and \</= Grade 2 peripheral neuropathy * Bisphosphonate therapy for symptomatic hypercalcemia. Use of bisphosphonate therapy for other reasons (example: bone metastasis or osteoporosis) is allowed * Uncontrolled pleural effusion, pericardial effusion, or ascites that require recurrent drainage procedures (one monthly or more frequently). Participants with indwelling catheters are allowed * Known clinically significant liver disease which includes active viral, alcoholic, or other hepatitis, cirrhosis, fatty liver, and inherited liver disease * History (within the previous year) of congestive heart failure, stroke, arrhythmia, or myocardial infarction * History of peripheral venous thrombosis or thromboembolic event (within 12 months prior to Cycle 1 Day 1) * Significant cardio- or cerebrovascular disease within 6 months prior to Cycle 1 Day 1 * Known hereditary or acquired coagulopathies * Clinically meaningful proteinuria * Requiring dialysis (peritoneal or hemodialysis) * Known primary central nervous system (CNS) malignancy or symptomatic or untreated CNS metastases: participants with asymptomatic-treated CNS metastases may be enrolled after consultation with the Medical Monitor, provided they meet the following criteria: 1. Radiographic demonstration of improvement upon completion of CNS-directed therapy and no evidence of interim progression between the completion of CNS-directed therapy and the screening radiographic study 2. No stereotactic radiation or whole-brain radiation within 28 days prior to Cycle 1 Day 1 * Pregnancy, lactation, or breastfeeding * Allergy or hypersensitivity to components of the RO7009789 formulation or to components of atezolizumab formulation * History of autoimmune diseases (participants with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible; participants with controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible for this study) * History of idiopathic pulmonary fibrosis, pneumonitis (excluding infectious disease-induced), organizing pneumonia, or evidence of active pneumonitis * History of radiation pneumonitis in the radiation field (fibrosis) is permitted * Participants with human immunodeficiency virus (HIV) infection, active hepatitis B (chronic or acute), or hepatitis C infection * Active tuberculosis * Severe infections within 4 weeks prior to Cycle 1 Day 1 * Signs or symptoms of infection within 2 weeks prior to Cycle 1 Day 1 * Received oral or IV antibiotics within 2 weeks prior to Cycle 1 Day 1 * Major surgical procedure within 28 days prior to Cycle 1 Day 1 or anticipation of need for a major surgical procedure during the course of the study * Administration of a live, attenuated vaccine within 4 weeks before Cycle 1 Day 1 or anticipation that such a live attenuated vaccine will be required during the study * Malignancies other than disease under study within 3 years prior to Cycle 1 Day 1 with the exception of those with a negligible risk of metastasis or death and with expected curative outcome * Previous treatment with any other compound that targets cluster of differentiation 40 (CD40) (like Chi Lob 7/4 and ADC1013) * Treatment with systemic immunostimulatory agents (including but not limited to interferon (IFN)-alpha, Interleukin-2 (IL-2) within 4 weeks or 5 times the half-life of the drug, whichever is shorter, prior to Cycle 1 Day 1 * Treatment with investigational agent within 4 weeks prior to Cycle 1 Day 1 (or within 5 times the half-life of the investigational product, whichever is longer) * Concomitant treatment with anticoagulants (example: coumadin, heparin) except low dose molecular weight heparin for prophylactic purposes and direct factor Xa inhibitors * Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor (TNF) agent within 2 weeks prior to Cycle 1 Day 1 1. Participants who have received acute, low-dose, systemic immunosuppressant medications (example: a one-time dose of dexamethasone for nausea) may be enrolled in the study after discussion with and approval by the Medical Monitor 2. The use of corticosteroids as premedication in case of dye allergy previous to computed tomography (CT) scan is allowed * History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins * Participants with prior allogeneic bone marrow transplantation or prior solid organ transplantation * Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participants at high risk from treatment complications

Locations (11)

University of Pennsylvania

Philadelphia, Pennsylvania, United States

University Health Network; Princess Margaret Hospital; Medical Oncology Dept

Toronto, Ontario, Canada

Jewish General Hospital / McGill University

Montreal, Quebec, Canada

Outcomes

Primary Outcomes

Part IA: Percentage of Participants with Adverse Events and Serious Adverse Events

Time frame: Baseline up to 28 Days After the Last Dose (Approximately 38 Months)

Part IB: Percentage of Participants with Adverse Events and Serious Adverse Events

Time frame: Baseline up to 28 Days After the Last Dose (Approximately 38 Months)

Part IB: Percentage of Participants With Dose-Limiting Toxicities (DLTs)

Time frame: Cycle 1 Day 1 up to Cycle 2 Day 2 (Cycle length = 21 days)

Part IB: Maximum Tolerated Dose (MTD) of Selicrelumab

Time frame: Cycle 1 Day 1 up to Cycle 2 Day 2 (Cycle length = 21 days)

Part IB: Recommended Part II Dose of Selicrelumab

Time frame: Cycle 1 Day 1 up to Cycle 2 Day 2 (Cycle length = 21 days)

Part II: Percentage of Participants with Adverse Events and Serious Adverse Events

Time frame: Baseline up to 28 days after the last dose (approximately 38 months)

Part II: Percentage of Participants With Best Overall Response, as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

Time frame: Baseline up to PD or death due to any cause, whichever occurs first (up to approximately 38 months)

Part II: Progression-Free Survival (PFS), as Determined by Investigator Using RECIST Version 1.1

Time frame: Baseline up to PD or death due to any cause, whichever occurs first (up to approximately 38 months)

Part II: Duration of Objective Response, as Determined by Investigator Using RECIST Version 1.1

Time frame: Baseline up to PD or death due to any cause, whichever occurs first (up to approximately 38 months)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

Part IA: Area Under the Concentration Time Curve (AUC) of Selicrelumab

Time frame: Pre Selicrelumab dose (1hour[Hr]) on Cycle(Cy)1 Day1(D1); 4,8,24,48,72Hr post D1dose; D8,15 of Cy1; D1 Cy2&3 (10 minutes pre ATZ dose); at radiographic disease progression (PD)(up to 38 months);28&150 days after last ATZ dose (up to38months)(Cy=21days)

Part IA: Maximum Serum Concentration (Cmax) of Selicrelumab

Time frame: Pre Selicrelumab dose (within 1 Hr) on Cy1 D1; 4, 8, 24, 48,72Hr post D1dose; D8, D15 of Cy1; D1 of Cy2 & 3 (10 minutes [min] pre ATZ dose); at radiographic PD (up to 38 months); 28 & 150 days after last ATZ dose (up to 38 months) (Cy=21days)

Part IA: Time to Cmax (Tmax) of Selicrelumab

Time frame: Pre Selicrelumab dose (within 1 Hr) on Cy1 D1; 4, 8, 24, 48,72Hr post D1dose; D8, D15 of Cy1; D1 of Cy2 & 3 (10 min pre ATZ dose); at radiographic PD (up to 38 months); 28 & 150 days after last ATZ dose (up to 38 months) (Cy=21days)

Part IA: Minimum Serum Concentration Under Steady-State (Cmin) of Selicrelumab

Part IA: Apparent Clearance (CL/F) of Selicrelumab

Part IA: Half-Life (t1/2) of Selicrelumab

Part IA: Cmax of Atezolizumab

Time frame: Pre ATZ (within 10 min) & at end of 60 min ATZ infusion on Cy2D1; pre ATZ dose (within 10 min) on D1 of Cy3,4,5,9,& every 8Cy thereafter(up to 38 months); at radiographic PD(up to 38 months); 28&150 days after last ATZ dose (up to 38 months) (Cy=21 days)

Part IA: Cmin of Atezolizumab

Part IB: AUC of SC Selicrelumab

Time frame: Pre ATZ dose (within 1 Hr) on Cy1D1, Pre Selicrelumab dose (within 1 Hr) on Cy1D2; Cy1 D3,4,5,9,15 post D2 dose; D1 of Cy2 & 3 (10 min pre ATZ dose); at radiographic PD (up to 38 months); 28 & 150 days after last ATZ dose (up to 38 months) (Cy=21 days)

Part IB: Cmax of SC Selicrelumab

Part IB: Tmax of SC Selicrelumab

Part IB: Cmin of SC Selicrelumab

Part IB: CL/F of SC Selicrelumab

Part IB: Apparent Volume of Distribution (V/F) of SC Selicrelumab

Part IB: t1/2 of SC Selicrelumab

Part IB: Cmax of Atezolizumab

Time frame: Pre ATZ (within 1 Hr) & at end of 60 min ATZ infusion on Cy1D1; pre ATZ dose (within 10 min) on D1 of Cy2,3,4,8,& every 8Cy thereafter (up to 38 months); at radiographic PD (up to 38 months); 28&150 days after last ATZ dose (up to 38 months) (Cy=21 days)

Part IB: Cmin of Atezolizumab

Part II: AUC of Selicrelumab

Time frame: Pre Selicrelumab (within 1Hr) on Cy1D2; Cy1,5D5,8,15; pre ATZ (10 min) on D1-Cy2,4,6,8 and thereafter except Cy 11, 15, 19; pre Selicrelumab(10 min) on D2 of Cy3,5,11,15,19; D8 of Cy11,15,19; 28&150 days after last ATZ (up to 38 months) (Cy=21days)

Part II: Cmax of Selicrelumab

Time frame: Pre Selicrelumab (within 1Hr) on Cy1D2; Cy1, 5D5, 8, 15; pre ATZ (10 min) on D1-Cy2,4,6,8 and thereafter except Cy 11, 15, 19; pre Selicrelumab(10 min) on D2-Cy3,5,11,15,19; D8-Cy 11,15,19; 28&150 days after last ATZ (up to 38 months) (Cy=21days)

Part II: Tmax of Selicrelumab

Time frame: Pre Selicrelumab (within 1Hr) on Cy1D2; Cy 1, 5 D5,8,15; pre ATZ (10 min) on D1-Cy2,4,6,8 and thereafter except Cy 11, 15, 19; pre Selicrelumab(10 min) on D2 of Cy3,5,11,15,19; D8 of Cy 11,15,19; 28&150 days after last ATZ (up to 38 months) (Cy=21days)

Part II: Cmin of Selicrelumab

Time frame: Pre Selicrelumab (within 1Hr) on Cy1D2; Cy1,5D5, 8,15; pre ATZ (10 min) on D1-Cy2,4,6,8 and thereafter except Cy11, 15, 19; pre Selicrelumab(10 min) on D2-Cy3,5,11,15,19; D8-Cy 11,15,19; 28&150 days after last ATZ (up to 38 months) (Cy=21days)

Part II: CL/F of Selicrelumab

Time frame: Pre Selicrelumab (within 1Hr) on Cy1D2; Cy1,5D5,8,15; pre ATZ (10 min) on D1-Cy2,4,6,8 and thereafter except Cy 11, 15, 19; pre Selicrelumab(10 min) on D2-Cy3,5,11,15,19; D8-Cy11,15,19; 28&150 days after last ATZ (up to 38 months) (Cy=21days)

Part II: V/F of Selicrelumab

Time frame: Pre Selicrelumab (within 1Hr) on Cy1D2; Cy 1,5D5,8,15; pre ATZ (10 min) on D1-Cy2,4,6,8 and thereafter except Cy 11, 15, 19; pre Selicrelumab(10 min) on D2-Cy3,5,11,15,19; D8-Cy 11,15,19; 28&150 days after last ATZ (up to 38 months) (Cy=21days)

Part II: t1/2 of Selicrelumab

Time frame: Pre Selicrelumab (within 1Hr) on Cy1D2; Cy1,5D5,8,15; pre ATZ (10 min) on D1-Cy2,4,6,8 and thereafter except Cy 11, 15, 19; pre Selicrelumab(10 min) on D2-Cy3,5,11,15,19; D8-Cy 11,15,19; 28&150 days after last ATZ (up to 38 months) (Cy=21days)

Part II: Cmax of Atezolizumab

Time frame: Cy1D1: pre ATZ dose (within 1 Hr), at end of ATZ infusion (60 min infusion); pre-ATZ dose (within 10 min)on D1 Cy2, 3, 4, 5, 6, 8, and thereafter (up to 38 months); 28 and 150 days after last ATZ dose (up to 38 months) (Cy = 21 days)

Part II: Cmin of Atezolizumab

Part IB: Percentage of Participants With Best Overall Response, as Determined by Investigator Using Unidimensional Immune-Related Response Criteria (irRC)

Time frame: Baseline up to PD or death due to any cause, whichever occurs first (up to approximately 38 months)

Part IB: Percentage of Participants With Best Overall Response, as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

Time frame: Baseline up to PD or death due to any cause, whichever occurs first (up to approximately 38 months)

Part IB: Percentage of Participants With Disease Control, as Determined by Investigator Using RECIST Version 1.1

Time frame: Baseline up to PD or death due to any cause, whichever occurs first (up to approximately 38 months)

Part Ib: Percentage of Participants With Disease Control, as Determined by Investigator Using Unidimensional irRC

Time frame: Baseline up to PD or death due to any cause, whichever occurs first (up to approximately 38 months)

Part IB: Duration of Objective Response, as Determined by Investigator Using RECIST Version 1.1

Time frame: First occurrence of response up to relapse or death due to any cause, whichever occurs first (up to approximately 38 months)

Part Ib: Duration of Objective Response, as Determined by Investigator Using Unidimensional irRC

Time frame: First occurrence of response up to relapse or death due to any cause, whichever occurs first (up to approximately 38 months)

Part IB: Progression-Free Survival (PFS), as Determined by Investigator Using RECIST Version 1.1

Time frame: Baseline up to PD or death due to any cause, whichever occurs first (up to approximately 38 months)

Part IA, IB, and II: Percentage of Participants With Auto-antibodies

Time frame: Pre Selicrelumab dose(within 1 Hr) on Cy1D1;pre ATZ dose(within 10 min) on D1 Cy2,3,4,5 and every 8 cycles thereafter, up to 38 months); at radiographic PD (up to 38 months); 28 & 150 days after last ATZ dose (up to 38 months overall) (Cy=21 days)

Part IA, IB, and II: Percentage of Participants With Anti-Therapeutic Antibodies (ATA) to Selicrelumab

Part IA, IB, and II: Percentage of Participants With ATA to ATZ

Time frame: Pre ATZ(within 10 min)on D1 Cy2,3,4,5(Part IA),9(Cy8 for Part II)& every 8 cycles thereafter(up to 38 months);pre ATZ(within 1Hr) on Cy1D1(for Part IB & II);at radiographic PD(up to 38 months),28&150 days after last ATZ dose(up to 38 months)(Cy=21 days)

Part IA: Levels of Circulating Ki67 T cells Assessed by Immunophenotyping by Flow Cytometry

Time frame: Cy1 D1: predose Selicrelumab D4 D8 D15 Cy2 D1: predose Atezo D3 D8 Cy3 D1: predose Atezo D8 PD at IRR/ISR (Cy=21 Days)

Part IB: Levels of Circulating Ki67 T Cells Assessed by Immunophenotyping by Flow Cytometry

Time frame: Cy1: D3 D4 D5 D9 D15; Cy2: D1 D8; Cy4-47: D1 PD at IRR/ISR (Cy = 21 days)

Part II: Levels of Circulating Ki67 T Cells Assessed by Immunophenotyping by Flow Cytometry

Time frame: Cy1: D1 pre-Atezo, D8, D15; Cy2D1: pre-Atezo; Cy3 D1 pre-Atezo, D8; Cy4D1: pre-Atezo; Cy5: D1 pre-Atezo, D8, D15; Cy6D1: Pre-Atezo; Cy11, 15 and 19: D1 pre Atezo and D8; After last Atezo dose SFU at IRR/ISR (Cy= 21 Days)

Part IA: Levels of Cluster of Differentiation 8 (CD8+) Cells Tumor-Infiltration Assessed by Immunophenotyping by Flow Cytometry

Time frame: Cy1 D1: predose Selicrelumab D4 D8 D15; Cy2 D1: predose Atezo D3 D8; Cy3 D1: predose Atezo D8 PD at IRR/ISR (Cy= 21 Days)

Part IB: Levels of CD8+ Cells Tumor-Infiltration Assessed by Immunophenotyping by Flow Cytometry

Time frame: Cy1: D1 predose, D3, D4, D5, D9, D15; Cy2: D1 predose, D8; Cy4-47: D1 predose, PD at IRR/ISR (Cy = 21 days)

Part IA: Levels of Programmed Death Ligand 1 (PD-L1) Expression on Both Tumor and Immune-Infiltrating Cells Assessed by Immunophenotyping by Flow Cytometry

Time frame: Cy1 D1: predose Selicrelumab D4 D8 D15; Cy2 D1: predose Atezo D3 D8; Cy3 D1: predose Atezo D8 PD at IRR/ISR (Cycle = 21 Days)

Part IB: Levels of PD-L1 Expression on Both Tumor and Immune-Infiltrating Cells Assessed by Immunophenotyping by Flow Cytometry

Time frame: Cy1: D1 predose, D3, D4, D5, D9, D15; Cy2: D1 predose, D8; Cy4-47: D1 predose, PD at IRR/ISR (Cy = 21 days)

Part II: Levels of PD-L1 Expression on Both Tumor and Immune-Infiltrating Cells Assessed by Immunophenotyping by Flow Cytometry

Time frame: Cy1: D1 pre-Atezo, D8, D15; Cy2D1: pre-Atezo; Cy3 D1 pre-Atezo, D8; Cy4D1: pre-Atezo; Cy5: D1 pre-Atezo, D8, D15; Cy6D1: Pre-Atezo; Cy11, 15 and 19: D1 pre-Atezo and D8; After last Atezo dose SFU at IRR/ISR (Cy= 21 Days)

Part IA: V/F of Selicrelumab

Part IB: PFS, as Determined by Investigator Using Unidimensional irRC

Time frame: Baseline up to PD or death due to any cause, whichever occurs first (up to approximately 38 months)

Part II: Levels of CD8+ Cells Tumor-Infiltration Assessed by Immunophenotyping by Flow Cytometry

Time frame: Part II: Pre ATZ (within 1 Hr) Cy1, 6, 11, 15, 19 D1; Cy1 D8, 15; pre ATZ (within 10 min) Cy2, 3, 4, 5 D1; Cy3, 5, 11, 15, 19 D8; Cy 5 D15; 28 days after last ATZ dose(up to 38 months); at radiographic tumor regression/PD (up to 38 months) (Cy= 21 days)

Part IB: AUC of IV Selicrelumab

Time frame: Pre ATZ(1 Hr) Cy1D1,2;end of 30-min Selicrelumab infusion,0.25,2,4,6,8,10Hr post infusion start Cy1D2;24,30-36,48,72Hr Post Cy1D2 dose;Cy 1D9;D1 Cy2,3(10min pre ATZ);at radiographic PD(up to 38mon);28&150days after last ATZ dose(up to38mon)(Cy=21days)

Part IB: Cmax of IV Selicrelumab

Time frame: Pre ATZ(1 Hr)Cy1D1,2;end of 30-min Selicrelumab infusion,0.25,2,4,6,8,10Hr post infusion start Cy1D2;24,30-36,48,72Hr Post Cy1D2 dose;Cy 1D9;D1 Cy2,3(10min pre ATZ);at radiographic PD(up to 38mon);28&150days after last ATZ dose(up to38mont)(Cy=21days)

Part IB: Cmin of IV Selicrelumab

Part IB: Total Clearance (CL) of IV Selicrelumab

Part IB: Volume of Distribution (Vss) of IV Selicrelumab

Part IB: t1/2 of IV Selicrelumab

Part IA: Percentage of Participants with Incidence of ADA Responses to RO7009789

Time frame: Pre-Dose Day 1 on Cycles 1, 2, 3, 4, 7 (Cycle length = 21 days); Safety Follow-up Visit (Up to 52 Days Post Final Dose)

Part IA: Percentage of Participants with Incidence of ADA Responses to Vanucizumab

Time frame: Pre-Dose Day 1 on Cycles 1, 2, 4, 6, 8 (Cycle length = 21 days); Safety Follow-up Visit (Up to 52 Days Post Final Dose)

Part IB: Percentage of Participants with Incidence of ADA Responses to RO7009789

Time frame: Pre-Dose Day 1 on Cycles 1, 2, 3, 4, 7 (Cycle length = 21 days); Safety Follow-up Visit (Up to 52 Days Post Final Dose)

Part IB: Percentage of Participants with Incidence of ADA Responses to Vanucizumab

Time frame: Pre-Dose Day 1 on Cycles 1, 2, 4, 6, 8 (Cycle length = 21 days); Safety Follow-up Visit (Up to 52 days post final dose)

Part II: Percentage of Participants with Incidence of ADA Responses to RO7009789

Time frame: Pre-Dose Day 1 on Cycles 1, 2, 3, 4, 7 (Cycle length = 21 days); Safety Follow-up Visit (Up to 52 Days Post Final Dose)